Ab­b­Vie hands over $20M for Alzheimer's, Parkin­son's drugs; Au­to­lus boost­ed by a PIM

Ab­b­Vie is pay­ing $20 mil­lion to buy in new drug can­di­dates from UK biotech Mis­sion Ther­a­peu­tics, which will aim to go af­ter Alzheimer’s and Parkin­son’s.

Mis­sion’s spe­cial­ty is deu­biq­ui­ty­lat­ing en­zyme (DUB) tar­gets — fol­low­ing their own path rather than mis­filed pro­teins like amy­loid, which has re­cent­ly been re­vived as a lead­ing drug tar­get fol­low­ing the ap­proval of Bio­gen’s ad­u­canum­ab and break­through ther­a­py des­ig­na­tions for 2 oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER